

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

A

DOENHOFF et al

Atty. Ref.: 687-102

Serial No. 10/020,441

Group:

Filed: December 18, 2001

Examiner:

For: SCHISTOSOMIASIS VACCINE

* * * * *



May 20, 2002

Assistant Commissioner for Patents
Washington, DC 20231


Sir:

SUBMISSION OF SEQUENCE LISTING

In response to the Notice mailed March 18, 2002 (copy attached), attached is a printed sequence listing for this application. Applicants submit that the Sequence Listing in the above-identified matter is identical to the sequence listing filed in parent application Serial No. 09/413,810 filed October 7, 1999. It is also hereby requested that the computer readable copy of the Sequence Listing filed in connection with the parent application be used in connection with the present case.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 
Leonard C. Mitchard
Reg. No. 29,009

LCM:lks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
Attachments: Notice; paper copy of sequence listing; preliminary amendment



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/020,441	12/18/2001	Michael Doenhoff	687-102

DOCKETED

CONFIRMATION NO. 1683

NIXON & VANDERHYE P.C.
8th Floor
1100 North Glebe Road
Arlington, VA 22201-4714

CLT/MATTER # 087-102

FORMALITIES LETTER

MAIL DATE 3-18-02



DUE DATE May 18, 2002

FINAL DEADLINE Oct 18, 2002

DOCKETED BY [signature]

Date Mailed: 03/18/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*